Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: A potential treatment for lymphangioleiomyomatosis

Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy

(2010) Anat Biran et al.   INTERNATIONAL JOURNAL OF CANCER

Therapeutic targeting of mTOR in tuberous sclerosis

(2009) Julian R. Sampson   BIOCHEMICAL SOCIETY TRANSACTIONS

The Rheb-mTOR Pathway Is Upregulated in Reactive Astrocytes of the Injured Spinal Cord

(2009) S. Codeluppi et al.   JOURNAL OF NEUROSCIENCE

Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling

(2009) A B Hanker et al.   ONCOGENE

New Derivatives of Farnesylthiosalicylic Acid (Salirasib) for Cancer Treatment: Farnesylthiosalicylamide Inhibits Tumor Growth in Nude Mice Models

(2008) Liat Goldberg et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges

(2007) Elena A. Goncharova et al.   JOURNAL OF CELLULAR BIOCHEMISTRY